OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil device, a localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company operates in one segment being the device development for new medical treatments. Geographically, it derives maximum revenue from Europe and the rest from Australia, the Middle East, and the United Kingdom.
Contact
7 Eden Park Drive
Level 5, Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
18
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.50 | 69.70 | -0.75% |
| CAC 40 | 8,371.62 | 10.26 | 0.12% |
| DAX 40 | 26,735.51 | 36.37 | -0.14% |
| Dow JONES (US) | 52,192.67 | 104.42 | -0.20% |
| FTSE 100 | 10,904.62 | 41.53 | 0.38% |
| HKSE | 23,637.60 | 370.95 | -1.55% |
| NASDAQ | 24,953.56 | 412.54 | -1.63% |
| Nikkei 225 | 61,142.35 | 322.99 | 0.53% |
| NZX 50 Index | 14,173.68 | 85.55 | -0.60% |
| S&P 500 | 7,519.47 | 72.93 | -0.96% |
| S&P/ASX 200 | 9,082.20 | 64.60 | -0.71% |
| SSE Composite Index | 3,634.35 | 21.48 | -0.59% |